Therapy for hepatitis C is undergoing a revolution. Several new drugs against the hepatitis C
virus (HCV) have reached the market and many others, including direct-acting antivirals and …

Around 71 million people are chronically infected with HCV worldwide. HCV antiviral drug
development has been remarkable. The availability of pangenotypic direct‐acting antivirals …

Background A simple treatment regimen that is effective in a broad range of patients who are
chronically infected with the hepatitis C virus (HCV) remains an unmet medical need …

Background In phase 2 trials, treatment with the combination of the nucleotide polymerase
inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained …

Background As the population that is infected with the hepatitis C virus (HCV) ages, the
number of patients with decompensated cirrhosis is expected to increase. Methods We …

One of the most exciting developments in antiviral research has been the discovery of the
direct-acting antivirals (DAAs) that effectively cure chronic hepatitis C virus (HCV) infections …

Treatment of chronic hepatitis C virus infection has been revolutionised by the development
of direct-acting antivirals (DAAs). All-oral, once-daily, 8-to 12-week treatment regimens are …

Background A safe, simple, effective, and pan-genotypic regimen to treat hepatitis C virus
(HCV) infection in patients coinfected with human immunodeficiency virus type 1 (HIV-1) …

ABSTRACT Pibrentasvir (ABT-530) is a novel and pan-genotypic hepatitis C virus (HCV)
NS5A inhibitor with 50% effective concentration (EC50) values ranging from 1.4 to 5.0 pM …

Background & Aims The fixed-dose combination of sofosbuvir/velpatasvir was highly
efficacious in patients infected with genotype (GT) 1–6 hepatitis C virus (HCV) in the …